PTPI - Petros Pharmaceuticals, Inc.

0.0664
-0.058   -86.747%

Share volume: 266,556,737
Last Updated: 05-21-2025
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$0.12
-0.06
-0.46%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
40%
Profitability 43%
Dept financing 40%
Liquidity 71%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
29.69%
2 Year
-89.53%
Key data
Stock price
$0.07
P/E Ratio 
0.00
DAY RANGE
$0.06 - $0.08
EPS 
-$14.90
52 WEEK RANGE
$0.01 - $0.33
52 WEEK CHANGE
$22.96
MARKET CAP 
3.698 M
YIELD 
N/A
SHARES OUTSTANDING 
31.160 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
2.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Shulman J. David
Region: US
Website: petrospharma.com
Employees: 20
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Petros Pharmaceuticals, Inc. is based in New York, New York. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED) It also develops and commercializes H100, a patented topical formulation candidate for the. treatment of acute Peyronie's disease.

Recent news